Alvocidib Biomarker-driven Phase 2 AML Study

Clinical trial NCT02520011 · TERMINATED

Trial details

NCT number: NCT02520011
Sponsor: Sumitomo Pharma America, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2016-03-14
Primary completion: 2020-02-12
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.